Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance

Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.